MedTrace Logo

Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech

NCT01818661 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-11-12

No results posted yet for this study

Summary

The study is designed to determine the relationship between structural and functional changes in the brain on imaging and progression of speech and language, neurological and neuropsychological features in patients with neurodegenerative apraxia of speech (AOS).

Conditions

  • PPA
  • Non-fluent Aphasia
  • Apraxia of Speech
  • Primary Progressive Non-fluent Aphasia
  • Primary Progressive Aphasia

Interventions

DRUG

AV-1451

This is used to assess Tau burden in the brain.

Sponsors & Collaborators

  • National Institute on Deafness and Other Communication Disorders (NIDCD)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Jennifer Whitwell, PhD · Mayo Clinic

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2028-06-30
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01818661 on ClinicalTrials.gov